Literature DB >> 22345169

Transgenic expression and genetic variation of Lmf1 affect LPL activity in mice and humans.

Maryam Hosseini1, Nicole Ehrhardt, Daphna Weissglas-Volkov, Ching-Mei Lai, Hui Z Mao, Jo-Ling Liao, Elina Nikkola, André Bensadoun, Marja-Riitta Taskinen, Mark H Doolittle, Päivi Pajukanta, Miklós Péterfy.   

Abstract

OBJECTIVE: Lipoprotein lipase (LPL) is a principal enzyme in lipoprotein metabolism, tissue lipid utilization, and energy metabolism. LPL is synthesized by parenchymal cells in adipose, heart, and muscle tissues followed by secretion to extracellular sites, where lipolyic function is exerted. The catalytic activity of LPL is attained during posttranslational maturation, which involves glycosylation, folding, and subunit assembly within the endoplasmic reticulum. A lipase-chaperone, lipase maturation factor 1 (Lmf1), has recently emerged as a critical factor in this process. Previous studies demonstrated that loss-of-function mutations of Lmf1 result in diminished lipase activity and severe hypertriglyceridemia in mice and human subjects. The objective of this study is to investigate whether, beyond its role as a required factor in lipase maturation, variation in Lmf1 expression is sufficient to modulate LPL activity in vivo. METHODS AND
RESULTS: To assess the effects of Lmf1 overexpression in adipose and muscle tissues, we generated aP2-Lmf1 and Mck-Lmf1 transgenic mice. Characterization of relevant tissues revealed increased LPL activity in both mouse strains. In the omental and subcutaneous adipose depots, Lmf1 overexpression was associated with increased LPL specific activity without changes in LPL mass. In contrast, increased LPL activity was due to elevated LPL protein level in heart and gonadal adipose tissue. To extend these studies to humans, we detected association between LMF1 gene variants and postheparin LPL activity in a dyslipidemic cohort.
CONCLUSIONS: Our results suggest that variation in Lmf1 expression is a posttranslational determinant of LPL activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22345169      PMCID: PMC3331946          DOI: 10.1161/ATVBAHA.112.245696

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  43 in total

1.  A general test of association for quantitative traits in nuclear families.

Authors:  G R Abecasis; L R Cardon; W O Cookson
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

2.  A fat-specific enhancer is the primary determinant of gene expression for adipocyte P2 in vivo.

Authors:  S R Ross; R A Graves; A Greenstein; K A Platt; H L Shyu; B Mellovitz; B M Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 3.  Identification of a fat cell enhancer: analysis of requirements for adipose tissue-specific gene expression.

Authors:  R A Graves; P Tontonoz; K A Platt; S R Ross; B M Spiegelman
Journal:  J Cell Biochem       Date:  1992-07       Impact factor: 4.429

4.  Identification of the active form of endothelial lipase, a homodimer in a head-to-tail conformation.

Authors:  Nathalie Griffon; Weijin Jin; Thomas J Petty; John Millar; Karen O Badellino; Jeffery G Saven; Dawn H Marchadier; Ellis S Kempner; Jeffrey Billheimer; Jane M Glick; Daniel J Rader
Journal:  J Biol Chem       Date:  2009-06-30       Impact factor: 5.157

5.  Lipase maturation factor 1 is required for endothelial lipase activity.

Authors:  Osnat Ben-Zeev; Maryam Hosseini; Ching-Mei Lai; Nicole Ehrhardt; Howard Wong; Angelo B Cefalù; Davide Noto; Maurizio R Averna; Mark H Doolittle; Miklós Péterfy
Journal:  J Lipid Res       Date:  2011-03-28       Impact factor: 5.922

6.  cld and lec23 are disparate mutations that affect maturation of lipoprotein lipase in the endoplasmic reticulum.

Authors:  V Briquet-Laugier; O Ben-Zeev; A White; M H Doolittle
Journal:  J Lipid Res       Date:  1999-11       Impact factor: 5.922

7.  Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes.

Authors:  P H Weinstock; C L Bisgaier; K Aalto-Setälä; H Radner; R Ramakrishnan; S Levak-Frank; A D Essenburg; R Zechner; J L Breslow
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 8.  Combined lipase deficiency (cld/cld) in mice affects differently post-translational processing of lipoprotein lipase, hepatic lipase and pancreatic lipase.

Authors:  R O Scow; C J Schultz; J W Park; E J Blanchette-Mackie
Journal:  Chem Phys Lipids       Date:  1998-06       Impact factor: 3.329

9.  Transgenic mice expressing human lipoprotein lipase driven by the mouse metallothionein promoter. A phenotype associated with increased perinatal mortality and reduced plasma very low density lipoprotein of normal size.

Authors:  E Zsigmond; E Scheffler; T M Forte; R Potenz; W Wu; L Chan
Journal:  J Biol Chem       Date:  1994-07-22       Impact factor: 5.157

10.  A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance.

Authors:  J C Brüning; M D Michael; J N Winnay; T Hayashi; D Hörsch; D Accili; L J Goodyear; C R Kahn
Journal:  Mol Cell       Date:  1998-11       Impact factor: 17.970

View more
  8 in total

1.  Increasing adipocyte lipoprotein lipase improves glucose metabolism in high fat diet-induced obesity.

Authors:  R Grace Walton; Beibei Zhu; Resat Unal; Michael Spencer; Manjula Sunkara; Andrew J Morris; Richard Charnigo; Wendy S Katz; Alan Daugherty; Deborah A Howatt; Philip A Kern; Brian S Finlin
Journal:  J Biol Chem       Date:  2015-03-17       Impact factor: 5.157

2.  Lipidomic Evaluation of Aryl Hydrocarbon Receptor-Mediated Hepatic Steatosis in Male and Female Mice Elicited by 2,3,7,8-Tetrachlorodibenzo-p-dioxin.

Authors:  Rance Nault; Kelly A Fader; Todd A Lydic; Timothy R Zacharewski
Journal:  Chem Res Toxicol       Date:  2017-03-20       Impact factor: 3.739

3.  Lipase maturation factor 1 (lmf1) is induced by endoplasmic reticulum stress through activating transcription factor 6α (Atf6α) signaling.

Authors:  Hui Z Mao; Nicole Ehrhardt; Candy Bedoya; Javier A Gomez; Diane DeZwaan-McCabe; Imran N Mungrue; Randal J Kaufman; D Thomas Rutkowski; Miklós Péterfy
Journal:  J Biol Chem       Date:  2014-07-17       Impact factor: 5.157

4.  The zinc finger and BTB domain containing protein ZBTB20 regulates plasma triglyceride metabolism by repressing lipoprotein lipase gene transcription in hepatocytes.

Authors:  Hao Li; Gan Liu; Xiaoqing Wan; Luting Zhou; Zhen-Bang Qin; Xian-Hua Ma; Kai Su; Ya-Jin Liu; Jinghao Yuan; Chun-Chun Wei; An-Jing Ren; Yu-Xia Chen; Stephen G Young; Hai Zhang; Zhifang Xie; Weiping J Zhang
Journal:  Hepatology       Date:  2021-12-01       Impact factor: 17.425

5.  Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.

Authors:  Nicole Ehrhardt; Michael E Doche; Shuang Chen; Hui Z Mao; Meghan T Walsh; Candy Bedoya; Maha Guindi; Weidong Xiong; Joseph Ignatius Irudayam; Jahangir Iqbal; Sebastien Fuchs; Samuel W French; M Mahmood Hussain; Moshe Arditi; Vaithilingaraja Arumugaswami; Miklós Péterfy
Journal:  Hum Mol Genet       Date:  2017-07-15       Impact factor: 5.121

6.  Embryonic viability, lipase deficiency, hypertriglyceridemia and neonatal lethality in a novel LMF1-deficient mouse model.

Authors:  Nicole Ehrhardt; Candy Bedoya; Miklós Péterfy
Journal:  Nutr Metab (Lond)       Date:  2014-08-16       Impact factor: 4.169

7.  Cell therapy could be a potential way to improve lipoprotein lipase deficiency.

Authors:  Wenjing Wu; Yajun Yin; Jie Zhong; Yongjia Peng; Shuncai Li; Libin Zheng; Hong Cao; Jin Zhang
Journal:  Lipids Health Dis       Date:  2017-10-02       Impact factor: 3.876

Review 8.  Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models.

Authors:  Debapriya Basu; Karin E Bornfeldt
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-06       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.